It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Standard contact tracing practice for COVID-19 is to identify persons exposed to an infected person during the contagious period, assumed to start two days before symptom onset or diagnosis. In the first large cohort study on backward contact tracing for COVID-19, we extended the contact tracing window by 5 days, aiming to identify the source of the infection and persons infected by the same source. The risk of infection amongst these additional contacts was similar to contacts exposed during the standard tracing window and significantly higher than symptomatic individuals in a control group, leading to 42% more cases identified as direct contacts of an index case. Compared to standard practice, backward traced contacts required fewer tests and shorter quarantine. However, they were identified later in their infectious cycle if infected. Our results support implementing backward contact tracing when rigorous suppression of viral transmission is warranted.
Backward contact tracing aims to identify individuals who were infected by the same person as infected an index case, and has been shown to be effective in modelling studies of SARS-COV-2. Here, the authors present empirical data of the effectiveness of backward contact tracing from a program amongst university students in Belgium.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 KU Leuven, Laboratory of Clinical Microbiology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Algemene Interne Geneeskunde, UZ Leuven, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)
2 KU Leuven, Laboratory of Clinical Microbiology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
3 KU Leuven, Laboratory of Clinical Microbiology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Laboratoriumgeneeskunde, UZ Leuven, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)